{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:20:38Z","timestamp":1787678438368,"version":"build-2784847793"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["GINOP-2.3.2-15-2016-00050"],"award-info":[{"award-number":["GINOP-2.3.2-15-2016-00050"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["TAMOP-4.2.4.A\/2-11\/1-2012-0001"],"award-info":[{"award-number":["TAMOP-4.2.4.A\/2-11\/1-2012-0001"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["WS1695414"],"award-info":[{"award-number":["WS1695414"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["WS1695450"],"award-info":[{"award-number":["WS1695450"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","award":["FK 128809"],"award-info":[{"award-number":["FK 128809"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Angiotensin-converting enzyme (ACE) and ACE2 have been implicated in the regulation of vascular physiology. Elevated synovial and decreased or normal ACE or ACE2 levels have been found in rheumatoid arthritis (RA). Very little is known about the effects of tumor necrosis factor \u03b1 (TNF-\u03b1) inhibition on ACE or ACE2 homeostasis. In this study, we assessed the effects of one-year anti-TNF therapy on ACE and ACE2 production in RA and ankylosing spondylitis (AS) in association with other biomarkers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>Forty patients including 24 RA patients treated with either etanercept (ETN) or certolizumab pegol (CZP) and 16 AS patients treated with ETN were included in a 12-month follow-up study. Serum ACE levels were determined by commercial ELISA, while serum ACE2 activity was assessed using a specific quenched fluorescent substrate. Ultrasonography was performed to determine flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT) and arterial pulse-wave velocity (PWV) in all patients. In addition, CRP, rheumatoid factor (RF) and ACPA were also measured. All assessments were performed at baseline and 6 and 12 months after treatment initiation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Anti-TNF therapy increased ACE levels in the full cohort, as well as in the RA and AS subsets. ACE2 activity increased in the full cohort, while the ACE\/ACE2 ratio increased in the full cohort and in the RA subset (<jats:italic>p<\/jats:italic> &amp;lt; 0.05). Uni- and multivariable regression analyses determined associations between ACE or ACE\/ACE2 ratios at different time points and disease duration, CRP, RF, FMD and IMT (<jats:italic>p<\/jats:italic> &amp;lt; 0.05). ACE2 activity correlated with CRP. The changes of ACE or ACE2 over 12 months were determined by treatment together with either RF or FMD (p &amp;lt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Anti-TNF treatment may increase ACE and ACE2 in the sera of RA and AS patients. ACE and ACE2 may be associated with disease duration, markers of inflammation and vascular pathophysiology. The effects of TNF inhibition on ACE and ACE2 may reflect, in part, the effects of these biologics on the cardiovascular system.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2021.785744","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T10:37:58Z","timestamp":1643279878000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Angiotensin Converting Enzyme Activity in Anti-TNF-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients"],"prefix":"10.3389","volume":"8","author":[{"given":"Bogl\u00e1rka","family":"So\u00f3s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikl\u00f3s","family":"Fagyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gnes","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edit","family":"V\u00e9gh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Pusztai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Cz\u00f3kolyov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Csongr\u00e1di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Hamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zs\u00f3fia","family":"Peth\u0151","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00f3ra","family":"Bodn\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Kerekes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Hodosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9va","family":"Szekanecz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szilvia","family":"Szamosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1ndor","family":"Sz\u00e1nt\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Sz\u0171cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Szekanecz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nrrheum.2015.112","article-title":"Cardiovascular comorbidity in rheumatic diseases","volume":"11","author":"Nurmohamed","year":"2015","journal-title":"Nat Rev Rheumatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.berh.2016.10.006","article-title":"Cardiovascular disease in inflammatory rheumatic diseases","volume":"30","author":"Castaneda","year":"2016","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"B4","first-page":"398","article-title":"Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity","volume":"35","author":"Kerekes","year":"2008","journal-title":"J Rheumatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3899\/jrheum.100668","article-title":"Assessment of subclinical vascular disease associated with ankylosing spondylitis","volume":"38","author":"Bodnar","year":"2011","journal-title":"J Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nrrheum.2012.16","article-title":"Validated methods for assessment of subclinical atherosclerosis in rheumatology","volume":"8","author":"Kerekes","year":"2012","journal-title":"Nat Rev Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.semarthrit.2008.02.001","article-title":"Endothelial dysfunction, carotid intima-media thickness, and accelerated atherosclerosis in rheumatoid arthritis","volume":"38","author":"Gonzalez-Gay","year":"2008","journal-title":"Semin Arthritis Rheum."},{"key":"B8","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.semarthrit.2008.01.012","article-title":"Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis","volume":"38","author":"Gonzalez-Juanatey","year":"2009","journal-title":"Semin Arthritis Rheum."},{"key":"B9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s10067-009-1118-y","article-title":"A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima-media in patients with systemic autoimmune diseases","volume":"28","author":"Soltesz","year":"2009","journal-title":"Clin Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1136\/ard.2010.129916","article-title":"Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis","volume":"70","author":"Greenberg","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"B11","first-page":"529","article-title":"Pro-inflammatory cytokines in atherosclerosis","volume":"10","author":"Szekanecz","year":"2008","journal-title":"Isr Med Assoc J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1741-7015-12-48","article-title":"Biologics, cardiovascular effects and cancer","volume":"12","author":"Damjanov","year":"2014","journal-title":"BMC Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nrrheum.2009.219","article-title":"Vascular effects of biologic agents in RA and spondyloarthropathies","volume":"5","author":"Szekanecz","year":"2009","journal-title":"Nat Rev Rheumatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1177\/039463200902200301","article-title":"Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events","volume":"22","author":"Murdaca","year":"2009","journal-title":"Int J Immunopathol Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/14740338.2019.1577817","article-title":"Update upon the infection risk in patients receiving TNF alpha inhibitors","volume":"18","author":"Murdaca","year":"2019","journal-title":"Expert Opin Drug Saf."},{"key":"B17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2217\/imt.12.151","article-title":"Effects of TNF-alpha inhibitors upon the mechanisms of action of VEGF","volume":"5","author":"Murdaca","year":"2013","journal-title":"Immunotherapy."},{"key":"B18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2174\/157339708786263942","article-title":"Targeting angiogenesis in rheumatoid arthritis","volume":"4","author":"Szekanecz","year":"2008","journal-title":"Curr Rheumatol Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00296-019-04497-0","article-title":"Effects of 1-year anti-TNF-alpha therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis","volume":"40","author":"Vegh","year":"2020","journal-title":"Rheumatol Int."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1002\/art.22809","article-title":"Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum."},{"key":"B21","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1472-8206.2010.00872.x","article-title":"Changes in arterial stiffness during continued infliximab treatment in patients with inflammatory arthropathies","volume":"25","author":"Angel","year":"2011","journal-title":"Fundam Clin Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/rheumatology\/kem089","article-title":"Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis","volume":"46","author":"Del Porto","year":"2007","journal-title":"Rheumatology (Oxford)."},{"key":"B23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2174\/1570161114666161013113457","article-title":"The effect of treatments for rheumatoid arthritis on endothelial dysfunction evaluated by flow-mediated vasodilation in patients with rheumatoid arthritis","volume":"15","author":"Kotani","year":"2017","journal-title":"Curr Vasc Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/annrheumdis-2013-203934","article-title":"Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis","volume":"74","author":"van Sijl","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/00004872-199509003-00002","article-title":"Recent advances in knowledge of the structure and function of the angiotensin I converting enzyme","volume":"13","author":"Corvol","year":"1995","journal-title":"J Hypertens Suppl."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e87843","DOI":"10.1371\/journal.pone.0087843","article-title":"New perspectives in the renin-angiotensin-aldosterone system (RAAS) I: endogenous angiotensin converting enzyme (ACE) inhibition","volume":"9","author":"Fagyas","year":"2014","journal-title":"PLoS ONE."},{"key":"B27","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e87845","DOI":"10.1371\/journal.pone.0087845","article-title":"New perspectives in the renin-angiotensin-aldosterone system (RAAS) IV: circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure","volume":"9","author":"Uri","year":"2014","journal-title":"PLoS ONE."},{"key":"B29","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1161\/CIRCULATIONAHA.110.955369","article-title":"Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction","volume":"122","author":"Zhong","year":"2010","journal-title":"Circulation."},{"key":"B30","doi-asserted-by":"publisher","first-page":"30113","DOI":"10.1074\/jbc.M505111200","article-title":"Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)","volume":"280","author":"Lambert","year":"2005","journal-title":"J Biol Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10741-011-9259-x","article-title":"Role of ACE2 in diastolic and systolic heart failure","volume":"17","author":"Wang","year":"2012","journal-title":"Heart Fail Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.cardfail.2009.01.014","article-title":"Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes","volume":"15","author":"Epelman","year":"2009","journal-title":"J Card Fail."},{"key":"B33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ijcard.2012.09.083","article-title":"Enzymatic activity of DPIV and renin-angiotensin system (RAS) proteases in patients with left ventricular dysfunction and primary prevention implantable cardioverter\/defibrillator (ICD)","volume":"168","author":"Lehmann","year":"2013","journal-title":"Int J Cardiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1053\/j.gastro.2020.10.041","article-title":"Altered intestinal ACE2 levels are associated with inflammation, severe disease, and response to anti-cytokine therapy in inflammatory bowel disease","volume":"160","author":"Potdar","year":"2021","journal-title":"Gastroenterology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1756-185X.2012.01820.x","article-title":"Patterns of angiotensin converting enzyme insertion\/deletion gene polymorphism among an Egyptian cohort of patients with rheumatoid arthritis","volume":"16","author":"Ahmed","year":"2013","journal-title":"Int J Rheum Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00296-007-0349-y","article-title":"Angiotensin-converting enzyme gene polymorphism in patients with psoriatic arthritis","volume":"27","author":"Al-Awadhi","year":"2007","journal-title":"Rheumatol Int."},{"key":"B37","first-page":"2705","article-title":"Angiotensin converting enzyme gene insertion-deletion polymorphism is associated with juvenile rheumatoid arthritis","volume":"30","author":"Alsaeid","year":"2003","journal-title":"J Rheumatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13813455.2019.1703005","article-title":"Genetic polymorphisms of ACE I\/D, IL-1beta G > A and IL-4 VNTR among Egyptian subjects with rheumatoid arthritis","volume":"13","author":"Elshazli","year":"2019","journal-title":"Arch Physiol Biochem"},{"key":"B39","first-page":"2107","article-title":"Significant association between insertion\/deletion polymorphism of the angiotensin-convertig enzyme gene and ankylosing spondylitis","volume":"18","author":"Inanir","year":"2012","journal-title":"Mol Vis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/1470320313478285","article-title":"The angiotensin-converting enzyme insertion\/deletion polymorphism and susceptibility to rheumatoid arthritis, vitiligo and psoriasis: a meta-analysis","volume":"16","author":"Song","year":"2015","journal-title":"J Renin Angiotensin Aldosterone Syst."},{"key":"B41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00296-015-3317-y","article-title":"Association of GSTM1, GSTT1, GSTP1-ILE105VAL and ACE I\/D polymorphisms with ankylosing spondylitis","volume":"36","author":"Inal","year":"2016","journal-title":"Rheumatol Int."},{"key":"B42","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11373-007-9203-1","article-title":"Association of angiotensin-converting enzyme (ACE) gene insertion-deletion polymorphism with spondylarthropathies","volume":"15","author":"Shehab","year":"2008","journal-title":"J Biomed Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/ard.45.11.921","article-title":"Serum and synovial fluid levels of angiotensin converting enzyme in polyarthritis","volume":"45","author":"Lowe","year":"1986","journal-title":"Ann Rheum Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/14397595.2020.1740418","article-title":"Renin-angiotensin system molecules are associated with subclinical atherosclerosis and disease activity in rheumatoid arthritis","volume":"31","author":"Braz","year":"2021","journal-title":"Mod Rheumatol."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa898","article-title":"Decreased serum ACE2 levels in patients with connective tissue diseases","author":"Tang","year":"2020","journal-title":"Rheumatology (Oxford)."},{"key":"B46","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00296-004-0564-8","article-title":"Renin and angiotensin-converting enzyme (ACE) as active components of the local synovial renin-angiotensin system in rheumatoid arthritis","volume":"25","author":"Cobankara","year":"2005","journal-title":"Rheumatol Int."},{"key":"B47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.amjms.2019.10.014","article-title":"Differential expression of renin-angiotensin system-related components in patients with rheumatoid arthritis and osteoarthritis","volume":"359","author":"Wu","year":"2020","journal-title":"Am J Med Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/ard.51.4.476","article-title":"Production of angiotensin converting enzyme by rheumatoid synovial membrane","volume":"51","author":"Veale","year":"1992","journal-title":"Ann Rheum Dis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00726-020-02935-z","article-title":"Angiotensin-(1-7) attenuates collagen-induced arthritis via inhibiting oxidative stress in rats","volume":"53","author":"Liu","year":"2021","journal-title":"Amino Acids."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.3899\/jrheum.200547","article-title":"Angiotensin-converting enzyme 2, a SARS-CoV-2 receptor, is upregulated by interleukin 6 through STAT3 signaling in synovial tissues","volume":"47","author":"Mokuda","year":"2020","journal-title":"J Rheumatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/ar3052","article-title":"Angiotensin-converting enzyme 2 autoantibodies: further evidence for a role of the renin-angiotensin system in inflammation","volume":"12","author":"Chappell","year":"2010","journal-title":"Arthritis Res Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"R85","DOI":"10.1186\/ar3012","article-title":"Autoantibodies to angiotensin-converting enzyme 2 in patients with connective tissue diseases","volume":"12","author":"Takahashi","year":"2010","journal-title":"Arthritis Res Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1002\/jcp.27205","article-title":"The potential therapeutic use of renin-angiotensin system inhibitors in the treatment of inflammatory diseases","volume":"234","author":"Ranjbar","year":"2019","journal-title":"J Cell Physiol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.3390\/jcm10091985","article-title":"Angiotensin-inhibiting drugs do not impact disease activity in patients with rheumatoid arthritis: a retrospective cross-sectional study","volume":"10","author":"Sluijsmans","year":"2021","journal-title":"J Clin Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"641295","DOI":"10.3389\/fimmu.2021.641295","article-title":"Anti-TNF-alpha agents modulate SARS-CoV-2 receptors and increase the risk of infection through notch-1 signaling","volume":"12","author":"Keewan","year":"2021","journal-title":"Front Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15761\/ROM.1000169","article-title":"Effects of one-year anti-TNF-\u03b1 therapy on biomarkers of angiogenesis and functional vascular parameters in arthritides","volume":"4","author":"Balogh","year":"2019","journal-title":"Rheumatol Orthop Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3899\/jrheum.200916","article-title":"Soluble vascular biomarkers in rheumatoid arthritis and ankylosing spondylitis: effects of one-year anti-TNF-alpha therapy","volume":"48","author":"Pusztai","year":"2020","journal-title":"J Rheumatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1186\/s12891-021-04708-5","article-title":"Peripheral quantitative computed tomography in the assessment of bone mineral density in anti-TNF-treated rheumatoid arthritis and ankylosing spondylitis patients","volume":"22","author":"Juhasz","year":"2021","journal-title":"BMC Musculoskelet Disord."},{"key":"B59","doi-asserted-by":"publisher","first-page":"19504","DOI":"10.1038\/s41598-021-99071-9","article-title":"Associations of vascular and bone status in arthritis patients","volume":"11","author":"Pusztai","year":"2021","journal-title":"Sci Rep."},{"key":"B60","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10067-019-04771-3","article-title":"Effects of 1-year anti-TNF-alpha therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis","volume":"39","author":"Gulyas","year":"2020","journal-title":"Clin Rheumatol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e93719","DOI":"10.1371\/journal.pone.0093719","article-title":"New perspectives in the renin-angiotensin-aldosterone system (RAAS) III: endogenous inhibition of angiotensin converting enzyme (ACE) provides protection against cardiovascular diseases","volume":"9","author":"Fagyas","year":"2014","journal-title":"PLoS ONE."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.785744\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T10:38:06Z","timestamp":1643279886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.785744\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":61,"alternative-id":["10.3389\/fmed.2021.785744"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.785744","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]},"article-number":"785744"}}